CYTK Cytokinetics, Incorporated - Common Stock
$76,48
Prezzo · Ago 18, 2026
Fondamentali al Ago 6, 2026
Intervallo 52 sett.
$35–$88
78% of range
Rating Analisti
BUY
28 analysts
Prezzo Obiettivo
$110
+44% upside
P/E (TTM)
-11.7
ROE
152.7%
Margine di Profitto Netto
-891.6%
Informazioni su Cytokinetics, Incorporated - Common Stock Panoramica della società da Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Leggi di più
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
CYTK Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$76.48
Capitalizzazione di Mercato
$9.40B
P/E (TTM)
-11.7
EPS (TTM)
$-6.54
Ricavi (TTM)
$88M
Rendimento div.
—
ROE
152.7%
D/E Debito/Patrimonio
-0.4
Intervallo 52 sett.
$35 – $88
CYTK Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$88M
2016-12-31
→
2025-12-31
EPS
$-6.54
2016-12-31
→
2025-12-31
Flusso di cassa libero
$-535M
2016-12-31
→
2025-12-31
Margini
-891.6%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
CYTK
Mediana dei peer
P/E (TTM)
-11.7
28.5
P/S (TTM)
106.8
20.1
P/B
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (Prezzo / FCF)
-17.6
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
CYTK
Mediana dei peer
Operating Margin (Margine Operativo)
-695.4%
—
Net Profit Margin (Margine di Profitto Netto)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
CYTK
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
-0.4
—
Current Ratio (Rapporto corrente)
4.5
5.0
Quick Ratio
0.7
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
CYTK
Mediana dei peer
Revenue YoY (Ricavi YoY)
376.6%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
-2.4%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
9.5%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
CYTK
Mediana dei peer
CYTK Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
28 analisti
- Acquisto forte 6 21,4%
- Compra 19 67,9%
- Mantieni 3 10,7%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
20 analisti · 2026-08-18
Mediana
$107.50
← Sotto tutti i target
$76.48
Basso
$85.00
Alto
$146.00
Target mediano
$107.50
+40,6%
Target medio
$109.90
+43,7%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.08%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $-1.50 | $-1.67 | 0.17% |
| 31 Marzo 2026 | $-1.67 | $-1.69 | 0.02% |
| 31 Dicembre 2025 | $-1.50 | $-1.49 | -0.01% |
| 30 Settembre 2025 | $-2.55 | $-1.61 | -0.94% |
| 30 Giugno 2025 | $-1.12 | $-1.41 | 0.28% |
| 31 Marzo 2025 | $-1.39 | $-1.41 | 0.02% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Stato Patrimoniale 26
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Flusso di cassa 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Efficienza 2
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Conto Economico 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Stato Patrimoniale 24
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Flusso di cassa 12
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Redditività 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidità e Solvibilità 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Efficienza 2
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Valutazione (TTM) 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $88M | $18M | $8M | $95M | $70M |
| Margine Operativo % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Utile netto | $-785M | $-590M | $-526M | $-389M | $-215M |
| EPS Diluito | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Rapporto corrente | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-535M | $-400M | $-416M | $-311M | $-191M |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 539 filer · $9.0B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 104 (+7 vs trimestre precedente) | 49 (-8 vs trimestre precedente) | 222 (+45 vs trimestre precedente) | 112 (-32 vs trimestre precedente) | +17.8M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571.778.157 | 6.711.799 | 6,37% | Azioni |
| STATE STREET CORP | $553.243.709 | 6.494.233 | 6,16% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $521.151.103 | 6.117.515 | 5,80% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $509.521.049 | 5.980.996 | 5,68% | Azioni |
| Avoro Capital Advisors LLC | $425.949.915 | 4.999.999 | 4,74% | Azioni |
| FMR LLC | $375.035.430 | 4.402.341 | 4,18% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $259.207.450 | 3.042.018 | 2,89% | Azioni |
| BANK OF AMERICA CORP /DE/ | $251.706.463 | 2.954.648 | 2,80% | Azioni |
| RTW INVESTMENTS, LP | $243.814.036 | 2.862.003 | 2,72% | Azioni |
| Polar Capital Holdings Plc | $191.988.358 | 2.253.649 | 2,14% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161.060.214 | 1.890.600 | 1,79% | Opzione Call |
| Capital Research Global Investors | $143.683.584 | 1.686.625 | 1,60% | Azioni |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136.597.224 | 1.603.442 | 1,52% | Azioni |
| Integral Health Asset Management, LLC | $136.304.000 | 1.600.000 | 1,52% | Azioni |
| Point72 Asset Management, L.P. | $135.257.185 | 1.587.712 | 1,51% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133.386.924 | 1.565.758 | 1,49% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131.998.327 | 1.549.458 | 1,47% | Azioni |
| PRINCIPAL FINANCIAL GROUP INC | $111.435.932 | 1.308.087 | 1,24% | Azioni |
| Capital International Investors | $111.245.191 | 1.305.848 | 1,24% | Azioni |
| ARMISTICE CAPITAL, LLC | $106.487.500 | 1.250.000 | 1,19% | Opzione Call |
| ARMISTICE CAPITAL, LLC | $102.342.325 | 1.201.342 | 1,14% | Azioni |
| Pictet Asset Management Holding SA | $99.038.455 | 1.160.463 | 1,10% | Azioni |
| Frazier Life Sciences Management, L.P. | $98.810.092 | 1.159.879 | 1,10% | Azioni |
| Holocene Advisors, LP | $97.506.685 | 1.144.579 | 1,09% | Azioni |
| Woodline Partners LP | $93.769.315 | 1.100.708 | 1,04% | Azioni |
| NORGES BANK | $86.512.319 | 1.015.522 | 0,96% | Azioni |
| Royalty Pharma Sub-Manager, LLC | $83.519.594 | 980.392 | 0,93% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81.937.000 | 961.815 | 0,91% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $77.218.175 | 906.423 | 0,86% | Azioni |
| CITADEL ADVISORS LLC | $77.062.874 | 904.600 | 0,86% | Opzione Call |
| Melqart Asset Management (UK) Ltd | $65.385.455 | 767.525 | 0,73% | Azioni |
| Siren, L.L.C. | $64.655.121 | 758.952 | 0,72% | Azioni |
| Fisher Asset Management, LLC | $63.355.547 | 743.697 | 0,71% | Azioni |
| Foresite Capital Management IV, LLC | $60.884.867 | 714.695 | 0,68% | Azioni |
| Balyasny Asset Management L.P. | $60.599.821 | 711.349 | 0,67% | Azioni |
| Deep Track Capital, LP | $59.633.000 | 700.000 | 0,66% | Azioni |
| JANE STREET GROUP, LLC | $59.633.000 | 700.000 | 0,66% | Opzione Call |
| BNP PARIBAS FINANCIAL MARKETS | $58.702.470 | 689.077 | 0,65% | Azioni |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56.251.809 | 660.310 | 0,63% | Azioni |
| CITADEL ADVISORS LLC | $54.601.338 | 640.936 | 0,61% | Azioni |
| GOLDMAN SACHS GROUP INC | $54.053.311 | 634.503 | 0,60% | Azioni |
| Qube Research & Technologies Ltd | $48.774.257 | 572.535 | 0,54% | Azioni |
| EVENTIDE ASSET MANAGEMENT, LLC | $48.081.832 | 564.398 | 0,54% | Azioni |
| Affinity Asset Advisors, LLC | $46.854.500 | 550.000 | 0,52% | Azioni |
| First Turn Management, LLC | $44.930.228 | 527.412 | 0,50% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $44.162.525 | 518.398 | 0,49% | Azioni |
| Caption Management, LLC | $43.651.356 | 512.400 | 0,49% | Opzione Call |
| D. E. Shaw & Co., Inc. | $40.874.247 | 479.801 | 0,46% | Azioni |
| Checkpoint Capital L.P. | $40.465.250 | 475.000 | 0,45% | Azioni |
| Hood River Capital Management LLC | $39.977.367 | 469.273 | 0,45% | Azioni |
| RP Management, LLC | $39.401.954 | 980.392 | 0,44% | Azioni |
| EMERALD ADVISERS, LLC | $39.013.272 | 457.956 | 0,43% | Azioni |
| ADAR1 Capital Management, LLC | $39.009.097 | 457.907 | 0,43% | Azioni |
| AMERIPRISE FINANCIAL INC | $38.010.006 | 446.179 | 0,42% | Azioni |
| Candriam S.C.A. | $37.708.477 | 443.066 | 0,42% | Azioni |
| MARSHALL WACE, LLP | $36.259.335 | 425.629 | 0,40% | Azioni |
| RHUMBLINE ADVISERS | $35.933.015 | 421.799 | 0,40% | Azioni |
| CITADEL ADVISORS LLC | $35.882.028 | 421.200 | 0,40% | Opzione Put |
| ALLIANCEBERNSTEIN L.P. | $35.327.299 | 535.993 | 0,39% | Azioni |
| GILDER GAGNON HOWE & CO LLC | $34.096.829 | 400.245 | 0,38% | Azioni |
| TD Asset Management Inc | $32.809.225 | 385.130 | 0,37% | Azioni |
| BlackRock, Inc. | $29.124.928 | 341.882 | 0,32% | Azioni |
| GSK plc | $29.001.573 | 340.434 | 0,32% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $27.040.243 | 317.411 | 0,30% | Azioni |
| CITIGROUP INC | $26.852.314 | 315.205 | 0,30% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24.671.024 | 289.600 | 0,27% | Opzione Put |
| Trails Edge Capital Partners, LP | $24.542.302 | 288.089 | 0,27% | Azioni |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23.833.521 | 279.769 | 0,27% | Azioni |
| Polaris Capital Management, LLC | $22.737.211 | 266.900 | 0,25% | Azioni |
| SEGALL BRYANT & HAMILL, LLC | $21.899.197 | 257.063 | 0,24% | Azioni |
| Alyeska Investment Group, L.P. | $21.297.500 | 250.000 | 0,24% | Azioni |
| ExodusPoint Capital Management, LP | $21.234.374 | 249.259 | 0,24% | Azioni |
| Capital World Investors | $21.196.550 | 248.815 | 0,24% | Azioni |
| Walleye Capital LLC | $20.422.428 | 239.728 | 0,23% | Azioni |
| E. Ohman J:or Asset Management AB | $19.823.223 | 300.762 | 0,22% | Azioni |
| Sarissa Capital Management LP | $19.476.393 | 228.623 | 0,22% | Azioni |
| Swiss National Bank | $18.946.256 | 222.400 | 0,21% | Azioni |
| SPHERA FUNDS MANAGEMENT LTD. | $18.740.693 | 219.987 | 0,21% | Azioni |
| BAKER BROS. ADVISORS LP | $17.997.836 | 211.267 | 0,20% | Azioni |
| California Public Employees Retirement System | $17.979.520 | 211.052 | 0,20% | Azioni |
| Nicholas Investment Partners, LP | $17.810.758 | 209.071 | 0,20% | Azioni |
| PINNACLE ASSOCIATES LTD | $17.245.864 | 202.440 | 0,19% | Azioni |
| Mirador Capital Partners LP | $17.239.900 | 202.370 | 0,19% | Azioni |
| Tri Locum Partners LP | $16.526.860 | 194.000 | 0,18% | Azioni |
| PFM Health Sciences, LP | $16.329.730 | 191.686 | 0,18% | Azioni |
| Rock Springs Capital Management LP | $16.014.016 | 187.980 | 0,18% | Azioni |
| PRUDENTIAL FINANCIAL INC | $15.933.512 | 187.035 | 0,18% | Azioni |
| DAFNA Capital Management LLC | $14.652.510 | 171.998 | 0,16% | Azioni |
| Ghisallo Capital Management LLC | $14.482.300 | 170.000 | 0,16% | Azioni |
| Impax Asset Management Group plc | $14.056.350 | 165.000 | 0,16% | Azioni |
| Lombard Odier Asset Management (Europe) Ltd | $13.494.096 | 158.400 | 0,15% | Opzione Call |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13.383.349 | 157.100 | 0,15% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13.330.276 | 156.477 | 0,15% | Azioni |
| JANE STREET GROUP, LLC | $12.735.905 | 149.500 | 0,14% | Opzione Put |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12.145.719 | 139.190 | 0,14% | Azioni |
| Retirement Systems of Alabama | $11.962.891 | 140.426 | 0,13% | Azioni |
| MetLife Investment Management, LLC | $11.930.519 | 140.046 | 0,13% | Azioni |
| Polymer Capital Management (HK) LTD | $11.777.943 | 138.255 | 0,13% | Azioni |
| Cinctive Capital Management LP | $11.742.419 | 137.838 | 0,13% | Azioni |
| TUDOR INVESTMENT CORP ET AL | $11.279.156 | 132.400 | 0,13% | Opzione Call |
Insider aziendali 52 insider · 18 dirigenti · 22 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 01 Luglio 2026 M | 63.221 | 0 | 5 | $-5.695.855 |
| Ching Jaw | SVP Finance & CFO | 06 Marzo 2023 A | 87.346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 Febbraio 2017 F | 40.323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 18 Agosto 2026 M | 153.902 | 0 | 22 | $-4.429.370 |
| Andrew Callos | EVP, Chief Commercial Officer | 30 Luglio 2026 M | 58.555 | 0 | 24 | $-15.318.893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 Marzo 2026 A | 107.943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 03 Dicembre 2024 A | 18.655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 Agosto 2024 A | 33.140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 Marzo 2022 M | 103.408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 07 Marzo 2022 F | 153.233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 Febbraio 2018 A | 32.548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 Febbraio 2018 A | 21.520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 Agosto 2017 M | 46.441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 Febbraio 2017 A | 29.004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 Febbraio 2017 A | 47.255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 Febbraio 2011 A | 42.000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 Dicembre 2009 M | 20.043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 Febbraio 2008 A | 47.896 | 0 | 0 | $0 |
| Robert Arthur Harrington | Direttore | 15 Luglio 2026 A | 21.932 | 0 | 2 | $-248.260 |
| James M Daly | Direttore | 15 Luglio 2026 A | 3.390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Direttore | 15 Luglio 2026 A | 10.434 | 0 | 6 | $-3.544.372 |
| Nancy Wysenski | Direttore | 15 Luglio 2026 A | 33.992 | 0 | 0 | $0 |
| Wendell Wierenga | Direttore | 15 Luglio 2026 A | 35.563 | 0 | 3 | $-1.881.925 |
| John T Henderson | Direttore | 15 Luglio 2026 A | 78.360 | 0 | 2 | $-2.078.525 |
| Lynne B Parshall | Direttore | 01 Giugno 2026 S | 15.784 | 0 | 3 | $-1.000.100 |
| Muna Bhanji | Direttore | 27 Maggio 2026 A | 26.361 | 0 | 0 | $0 |
| Robert E Landry | Direttore | 27 Maggio 2026 A | 10.184 | 0 | 0 | $0 |
| Wendall Wierenga | Direttore | 15 Luglio 2025 A | 32.345 | 0 | 0 | $0 |
| COSTA SANTO J | Direttore | 15 Maggio 2024 A | 20.600 | 0 | 0 | $0 |
| Sandford D Smith | Direttore | 02 Gennaio 2024 A | 18.801 | 0 | 0 | $0 |
| Robert Califf | Direttore | 03 Gennaio 2022 A | 6.003 | 0 | 0 | $0 |
| GAGE L PATRICK | Direttore | 08 Novembre 2021 M | 28.932 | 0 | 0 | $0 |
| Denise Gilbert | Direttore | 20 Maggio 2015 J | — | 0 | 0 | $0 |
| Stephen M Dow | Direttore | 02 Gennaio 2013 A | 1.421.052 | 0 | 0 | $0 |
| James A Spudich | Direttore | 18 Maggio 2011 A | 180.600 | 0 | 0 | $0 |
| Grant A Heidrich III | Direttore | 03 Gennaio 2011 A | 93.755 | 0 | 0 | $0 |
| Michael Schmertzler | Direttore | 03 Giugno 2010 S | 4.340.923 | 0 | 0 | $0 |
| Mark Mcdade | Direttore | 21 Maggio 2009 A | — | 0 | 0 | $0 |
| Charles J Homcy | Direttore | 22 Maggio 2008 A | — | 0 | 0 | $0 |
| William J Rutter | Direttore | 29 Aprile 2004 C | 172.413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Proprietario del 10% | 29 Aprile 2004 C | 1.615.716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Proprietario del 10% | 29 Aprile 2004 C | 771.052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Proprietario del 10% | 29 Aprile 2004 C | 650.000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Proprietario del 10% | 29 Aprile 2004 C | 755.631 | 0 | 0 | $0 |
| Robert I Blum | — | 10 Agosto 2026 M | 377.820 | 0 | 19 | $-9.702.097 |
| Elisabeth Schnieders | — | 28 Febbraio 2017 A | 43.919 | 0 | 0 | $0 |
| James H Sabry | — | 03 Giugno 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 29 Aprile 2004 C | 24.050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 29 Aprile 2004 C | 625.950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 29 Aprile 2004 C | 1.742.951 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 84 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,16% | 43.268 NS | 31 Maggio 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,52% | 17.069 NS | 31 Maggio 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,81% | 58.136 SH | 08 Agosto 2026 | Giornaliero |
| FMED · Fidelity Covington Trust | 1,55% | 8.262 NS | 31 Maggio 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1,40% | 3.663 NS | 31 Maggio 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,24% | 189.801 NS | 30 Aprile 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,98% | 48.338 NS | 30 Aprile 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 76.297 NS | 30 Aprile 2026 | N-PORT |
| IBB · iShares Trust | 0,75% | 874.995 SH | 08 Agosto 2026 | Giornaliero |
| BBC · ETFis Series Trust I | 0,75% | 4.355 NS | 30 Aprile 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,71% | 7.377 SH | 08 Agosto 2026 | Giornaliero |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102.933 SH | 08 Agosto 2026 | Giornaliero |
| IWN · iShares Trust | 0,62% | 1.099.434 SH | 08 Agosto 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 41.612 NS | 30 Aprile 2026 | N-PORT |
| BIB · ProShares Trust | 0,47% | 4.553 NS | 31 Maggio 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,47% | 94.565 NS | 30 Aprile 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,41% | 178 NS | 29 Maggio 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,37% | 21.543 SH | 08 Agosto 2026 | Giornaliero |
| XJH · iShares Trust | 0,35% | 18.349 SH | 08 Agosto 2026 | Giornaliero |
| IQSM · New York Life Investments ETF Trust | 0,34% | 16.959 NS | 30 Aprile 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761.130 SH | 08 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,34% | 3.349.200 SH | 08 Agosto 2026 | Giornaliero |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72.343 SH | 08 Agosto 2026 | Giornaliero |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1.797.986 SH | 08 Agosto 2026 | Giornaliero |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219.413 SH | 08 Agosto 2026 | Giornaliero |
| IJK · iShares Trust | 0,32% | 429.311 SH | 08 Agosto 2026 | Giornaliero |
| ISCG · iShares Trust | 0,32% | 38.968 SH | 08 Agosto 2026 | Giornaliero |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53.623 SH | 08 Agosto 2026 | Giornaliero |
| IJH · iShares Trust | 0,30% | 4.684.495 SH | 08 Agosto 2026 | Giornaliero |
| IJJ · iShares Trust | 0,29% | 317.724 SH | 08 Agosto 2026 | Giornaliero |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,26% | 55.086 NS | 30 Aprile 2026 | N-PORT |
| ITWO · ProShares Trust | 0,25% | 6.062 NS | 31 Maggio 2026 | N-PORT |
| RSSL · Global X Funds | 0,23% | 51.834 NS | 30 Aprile 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,23% | 14.028 NS | 30 Aprile 2026 | N-PORT |
| MVV · ProShares Trust | 0,22% | 4.565 NS | 31 Maggio 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,21% | 635.330 NS | 31 Maggio 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,20% | 19.862 NS | 30 Aprile 2026 | N-PORT |
| ESML · iShares Trust | 0,20% | 72.711 SH | 08 Agosto 2026 | Giornaliero |
| SCHM · SCHWAB STRATEGIC TRUST | 0,19% | 356.940 NS | 31 Maggio 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,19% | 37.821 NS | 30 Aprile 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40.586 SH | 08 Agosto 2026 | Giornaliero |
| ISCB · iShares Trust | 0,16% | 5.525 SH | 08 Agosto 2026 | Giornaliero |
| MIDU · Direxion Shares ETF Trust | 0,15% | 2.025 NS | 30 Aprile 2026 | N-PORT |
| UMDD · ProShares Trust | 0,15% | 638 NS | 31 Maggio 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11.444 NS | 30 Aprile 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47.609 NS | 30 Aprile 2026 | N-PORT |
| UWM · ProShares Trust | 0,15% | 4.765 NS | 31 Maggio 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,15% | 2.868 NS | 30 Aprile 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3.113.794 SH | 08 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,14% | 333.056 SH | 08 Agosto 2026 | Giornaliero |